Analysts Set Sana Biotechnology, Inc. (NASDAQ:SANA) PT at $8.33

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have earned a consensus rating of “Moderate Buy” from the nine brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation and eight have issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $8.3333.

SANA has been the subject of a number of analyst reports. Citigroup reiterated an “outperform” rating on shares of Sana Biotechnology in a research note on Thursday, October 30th. JMP Securities set a $8.00 price target on shares of Sana Biotechnology in a report on Thursday, October 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sana Biotechnology in a research note on Monday, December 8th. Citizens Jmp increased their target price on shares of Sana Biotechnology from $5.00 to $8.00 and gave the stock a “market outperform” rating in a research report on Thursday, October 30th. Finally, Wedbush raised their target price on Sana Biotechnology from $5.00 to $6.00 and gave the company an “outperform” rating in a report on Friday, November 7th.

Institutional Investors Weigh In On Sana Biotechnology

Several institutional investors and hedge funds have recently added to or reduced their stakes in SANA. Nisa Investment Advisors LLC boosted its position in Sana Biotechnology by 673.8% during the second quarter. Nisa Investment Advisors LLC now owns 10,911 shares of the company’s stock worth $30,000 after purchasing an additional 9,501 shares during the period. Hoey Investments Inc. acquired a new stake in shares of Sana Biotechnology in the second quarter worth $33,000. Mercer Global Advisors Inc. ADV bought a new stake in shares of Sana Biotechnology during the 3rd quarter worth $36,000. TD Waterhouse Canada Inc. bought a new position in Sana Biotechnology in the 3rd quarter worth $37,000. Finally, Lyell Wealth Management LP bought a new position in Sana Biotechnology in the 3rd quarter worth $37,000. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Sana Biotechnology Price Performance

Shares of SANA stock opened at $4.36 on Friday. Sana Biotechnology has a fifty-two week low of $1.26 and a fifty-two week high of $7.30. The stock’s 50-day moving average is $4.54 and its two-hundred day moving average is $3.84. The firm has a market cap of $1.16 billion, a P/E ratio of -4.49 and a beta of 1.95.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.03. As a group, research analysts expect that Sana Biotechnology will post -1.16 EPS for the current year.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.